Cancer Gene Therapy Market by Therapy, End User, Geography and Forecast Report, 2014-2024

The global cancer gene therapy market is expected to attain lucrative growth in the forecast period mainly due to rise in funding for R&D activities for cancer gene therapy, increasing prevalence of cancer, and rapid technological advancements being witnessed in the market. Gene therapy is used for the treatment of cancer, where a functional gene is inserted into the cells of a patient to correct a genetic abnormality and provide new function to the cells.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/cancer-gene-therapy-market/report-sample

Increasing funding for R&D activities for cancer gene therapy, rising prevalence of cancer, rapid technological advancements, growing geriatric population, ethical acceptance of gene therapy for treatment of diseases, growing popularity of DNA vaccines and favorable government regulations are some of the key factors characterizing the growth in the cancer gene therapy market, globally. According to the American Cancer Society (ACS), around 1,688,780 new cancer cases are expected to be diagnosed, in the U.S., in 2017. Almost, 600,920 Americans are expected to die of cancer in 2017, indicating that around 1,650 cancer patients are dying per day, due to the disease. In 2013, the World Health Organization (WHO) launched the Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020, that aimed at reducing the rate of premature mortality from cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases by 25%, by 2025.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cancer-gene-therapy-market

Innovation therapies with better success rates, ethical acceptance of gene therapy for cancer treatment and untapped markets in developing economies are expected to offer various growth opportunities for the players in the cancer gene therapy market. For instance, in August 2017, the United States Food and Drug Administration (USFDA) approved a breakthrough treatment for children suffering with acute lymphoblastic leukemia (ALL) using CAR T therapy, also known as Kymriah, developed at the University of Pennsylvania’s Abramson Cancer Center.

North America is expected to lead the global cancer gene therapy market throughout the forecast period (2018–2023) followed by the Europe. This is mainly due to strong healthcare infrastructure and high expenditure in R&D in North America. The healthcare industry in the region is undergoing major transformation following the implementation of various healthcare reforms.

Browse full report at: https://www.psmarketresearch.com/market-analysis/cancer-gene-therapy-market

In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and initiated a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, the U.K. Some of the other key players operating in the cancer gene therapy industry include Genelux Corporation, Cell Genesys, Advantagene Inc., GenVec, Inc., BioCanCell Ltd., Adaptimmune Therapeutics plc, Bluebird bio, Inc., and Achieve Life Sciences, Inc.

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.